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 ABSTRACT 30 
Aims 31 
Retinal hemorrhage is an important finding on fundus photography. Diabetes mellitus is a 32 
cause of retinal hemorrhage, although other causes exist. We sought to better characterize the 33 
association between retinal hemorrhage and HbA1c in the Japanese population. 34 
Methods 35 
We conducted a prospective study of 11,644 Japanese men and women aged 30–78 years 36 
between 2001 and 2011. Fundus photography was performed as part of an annual 37 
cardiovascular disease risk survey. HbA1c was determined by the latex coagulation method 38 
throughout the study. We used logistic regression models to examine the association between 39 
HbA1c and the risk of retinal hemorrhage and diabetic retinal hemorrhage. 40 
Results 41 
During a median follow-up period of 4.6 years, 509 retinal hemorrhages, including 96 42 
diabetic retinal hemorrhages, were diagnosed. HbA1c was positively associated with the risk 43 
of retinal hemorrhage and diabetic retinal hemorrhage among subjects not taking medication 44 
for diabetes mellitus at baseline, but not among subjects who were taking medication at 45 
baseline.  46 
Conclusions 47 
HbA1c was positively associated with the risk of retinal hemorrhage and the subcategory of 48 
diabetic retinal hemorrhage among subjects not taking medication for diabetes mellitus at 49 
baseline. The association was evident for diabetic retinal hemorrhage, compared with retinal 50 
hemorrhage. 51 
 52 
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 1. Introduction 56 
Retinal hemorrhage is an important finding on fundus photography, because severe retinal 57 
hemorrhage may damage retinal tissue and impair vision. Diabetes mellitus is a well-known 58 
cause of retinal hemorrhage, but the association between diabetes mellitus and the risk of 59 
retinal hemorrhage is unclear. Epidemiological studies have examined the association 60 
between hemoglobin A1c (HbA1c), hemoglobinA1, plasma glucose level and duration of 61 
diabetes mellitus and the risk of diabetic retinopathy, which includes retinal hemorrhage (1-5). 62 
However, these studies did not specifically focus on retinal hemorrhage. 63 
The aim of the present study was to investigate the association between 64 
HbA1c and the risk of retinal hemorrhage in order to develop prevention strategies for retinal 65 
hemorrhage at the population level. We included all retinal hemorrhages and retinal 66 
hemorrhages suspected to be caused by diabetes mellitus (diabetic retinal hemorrhage) as 67 
outcomes. We also investigated the association between cardiovascular risk factors and the 68 
risk of retinal hemorrhage. We analyzed the data from annual health check-ups for Japanese 69 
residents and workers.  70 
71 
 2. Material and Methods 72 
2.1 Study subjects  73 
Study subjects consisted of Japanese residents and workers between 30 and 78 years of age 74 
(mean age; 49.0 years). The residents were from two communities that participated in the 75 
Circulatory Risk in Community Study (CIRCS) (6) in Ikawa, Akita Prefecture and the 76 
Minami-Takayasu district of Yao city, Osaka Prefecture. The workers were employees of 20 77 
companies in Osaka Prefecture. At baseline, there were 18,478 subjects, including 7,020 78 
residents and 11,458 workers. We excluded 1,100 subjects who did not undergo fundus 79 
photography and 160 individuals who were diagnosed with retinal hemorrhage caused by 80 
diabetes mellitus or hypertension at the time of the first cardiovascular disease risk survey. 81 
HbA1c was not determined in 39 subjects, who were also excluded from the analysis. In 82 
addition, 4,618 subjects were excluded because they only underwent a single health check-up. 83 
Of the remaining 12,561 subjects, we used the data from 11,644 subjects (6,999 males and 84 
4,645 females; 4,834 residents and 6,810 workers) (Supplemental Table 1) who had complete 85 
information on Scott classification for diabetic retinopathy, Scheie classification for 86 
hypertensive retinopathy, and accessory information about spot bleeding, retinal vein 87 
occlusion, etc. The study was approved by the ethics committee of the Osaka Medical Center 88 
for Health Science and Promotion. 89 
 90 
2.2 Risk factor survey 91 
Annual cardiovascular disease risk surveys were performed from July 2001 to February 2011. 92 
Fundus photography with digital image storage was conducted during the study period based 93 
on the following criteria. In workers, a single eye, usually the right eye, was examined with 94 
fundus photography annually. Subjects diagnosed with diabetes mellitus during the previous 95 
survey underwent annual fundus photography of both eyes. Subjects with any retinal 96 
 hemorrhage during the previous 3 years also underwent fundus photography of both eyes. 97 
Residents underwent fundus photography of a single eye, usually the right eye, biennially. 98 
Subjects diagnosed with hyperglycemia or hypertension during the previous survey 99 
underwent annual fundus photography of a single eye, usually the right eye. Subjects with 100 
retinal changes related to hypertension, atherosclerosis, or diabetes mellitus during the 101 
previous survey also underwent annual fundus photography of a single eye, usually the right 102 
eye. Subjects diagnosed with diabetes mellitus during the previous survey underwent annual 103 
fundus photography of both eyes. Subjects with any retinal hemorrhage during the previous 3 104 
years also underwent fundus photography of both eyes. Fundus photography for the right eye 105 
represented 98% of single-eye examinations. We used the data from one eye for analysis. In 106 
subjects who underwent fundus photography of both eyes, we used information from the right 107 
eye only. 108 
Fundus photography was performed using a digital camera (CR6-45NM, 109 
Canon Inc., Tokyo, Japan). Well-trained physicians evaluated the photographs displayed on a 110 
14–15 inch monitor. When physicians identified a new hemorrhage in the retina during the 111 
follow-up period, they checked blood test data and medical history. When subjects with 112 
retinal hemorrhage met the following criteria, they were considered to have diabetic retinal 113 
hemorrhage: borderline to high blood glucose (fasting glucose >110 mg/dL or non-fasting 114 
glucose) >140 mg/dL, high HbA1c (HbA1c ≥6.0%, Japan Diabetes Society [JDS] value 115 
equivalent to a National Glycohemoglobin Standardization Program [NGSP] value of 6.4%), 116 
or medication for diabetes mellitus at time of the survey when retinal hemorrhage was 117 
diagnosed. We defined retinal hemorrhage that did not meet these criteria as non-diabetic 118 
retinal hemorrhage. We used the Scott classification to evaluate the severity of diabetic retinal 119 
hemorrhage (7). Medical technologists also verified the presence of hemorrhages in the 120 
 photographs. The final diagnosis of all retinal hemorrhages was based on consensus between 121 
the physicians and medical technologists.  122 
HbA1c was determined using the latex coagulation method (AU2700, 123 
Olympus Corp., Tokyo, Japan) at the Osaka Medical Center for Health Science and 124 
Promotion. We used the following formula to calculate the NGSP HbA1c value based on the 125 
JDS value stored in our database: HbA1c (NGSP) = 1.02 × HbA1c (JDS) + 0.25% (8). The 126 
HbA1c values reported in the present study are the calculated NGSP values. 127 
Body mass index (BMI) was calculated by dividing weight in kilograms by height in 128 
meters squared. Weight was determined with subjects wearing light clothing. Height was 129 
determined with subjects in their socks. Well-trained observers monitored arterial systolic 130 
blood pressure (SBP) and fifth-phase diastolic blood pressure (DBP) using a standard 131 
mercury sphygmomanometer on the right arm after at least 5 minutes of rest. Subjects were 132 
interviewed to determine their alcohol use and categorized as never, past, or current drinkers. 133 
Smoking habit was also determined during the interview, and subjects were categorized as 134 
never, past, or current smokers. Any history of diabetes mellitus, hypertension, cardiovascular 135 
disease, and medication use were assessed similarly. 136 
 137 
2.3 Statistical Analysis 138 
The follow-up period extended from the day of the first cardiovascular disease risk survey 139 
(baseline survey) to the day of the endpoint survey. For subjects diagnosed with retinal 140 
hemorrhage, we defined the endpoint survey as the survey in which the subject was first 141 
diagnosed with retinal hemorrhage. For subjects who did not develop retinal hemorrhage, we 142 
defined the endpoint as the final survey. The follow-up period ranged from 0.3 to 9.1 years 143 
(median, 4.6 years). 144 
 Subjects were stratified into two groups according to the use of medication for 145 
diabetes mellitus at baseline. Subjects were also divided into five categories according to 146 
their HbA1c level during the baseline survey: <5.7%, ≥5.7 to <6.5%, ≥6.5 to <7.3%, ≥7.3 to 147 
<8.1%, and ≥8.1%. Age- and sex-adjusted mean and proportion values of confounding 148 
variables according to HbA1c categories were calculated by analysis of covariance. Odds 149 
ratios (ORs) adjusted for age, sex, and multiple variables, respectively, and corresponding 150 
95% confidence intervals (95% CIs) were also determined for the incidence of retinal 151 
hemorrhage and diabetic retinal hemorrhage using logistic regression. While calculating ORs, 152 
subjects with HbA1c <5.7% at baseline were used as the referent group. We considered the 153 
following as confounding variables: baseline age; sex; BMI; current alcohol use (yes or no); 154 
current smoking (yes or no); hypertension (SBP ≥140 mmHg, DBP ≥90 mmHg or on 155 
anti-hypertensive therapy); serum low-density lipoprotein (LDL) cholesterol level (10 156 
mg/dL); serum high-density lipoprotein (HDL) cholesterol level (10 mg/dL); and initiation of 157 
medication for diabetes mellitus, hypertension, and hypercholesterolemia after the baseline 158 
survey (yes or no). We also investigated the relationship between confounding variables and 159 
the risk of retinal hemorrhage. When we tested the interaction between HbA1c and sex and 160 
subject background (resident or worker) status using an interaction term generated by 161 
multiplying HbA1c as a continuous variable with either sex or subject background status, we 162 
found no significant relationships. We present the combined data (P for interaction=0.45 for 163 
sex, P for interaction=0.14 for background status).  164 
SAS software (version 9.3, SAS Institute Inc., Cary, NC) was used for all analyses. 165 
Two-sided P values < 0.05 were considered statistically significant and P values between 166 
0.05 and 0.10 inclusive were considered borderline significant. 167 
 3. Results 168 
During a median follow-up period of 4.6 years for 11,644 subjects, 509 cases of retinal 169 
hemorrhage were diagnosed, including 96 cases of diabetic retinal hemorrhage. Table 1 170 
shows the number of cases stratified by use of medication for diabetes mellitus at baseline. 171 
The median follow-up for subjects who developed retinal hemorrhage was 3.1 years, 172 
compared to 4.8 years for those who did not have retinal hemorrhage. 173 
Table 2 shows the characteristics of subjects at the baseline cardiovascular 174 
disease risk survey stratified by use of medication for diabetes mellitus. Among subjects not 175 
taking medication for diabetes mellitus at baseline, those with baseline HbA1c ≥8.1% were 176 
older, had higher BMI, and there was a higher proportion of current smokers, higher systolic 177 
blood pressure, higher serum LDL cholesterol, and lower HDL cholesterol, compared to 178 
subjects whose baseline HbA1c was <5.7 %. Among subjects on medication for diabetes 179 
mellitus at baseline, subjects with baseline HbA1c ≥8.1% were younger than subjects whose 180 
baseline HbA1c was <5.7 %. 181 
Table 3 presents the multivariable-adjusted ORs and 95% CIs for retinal 182 
hemorrhage and diabetic retinal hemorrhage according to HbA1c category, stratified by use 183 
of medication for diabetes mellitus at baseline. For subjects not taking medication for 184 
diabetes mellitus at baseline, compared with the referent group whose baseline HbA1c was < 185 
5.7%, subjects with baseline HbA1c from ≥7.3 to <8.1% and ≥8.1% were at a significantly 186 
higher risk of retinal hemorrhage (P<0.001 and P<0.001, respectively) and subjects with 187 
baseline HbA1c from ≥5.7 to <6.5%, ≥6.5 to <7.3%, ≥7.3 to <8.1%, and ≥8.1% were at a 188 
significantly higher risk of diabetic retinal hemorrhage (P<0.001, P<0.001, P<0.001 and 189 
P<0.001, respectively). Among subjects receiving glucose-lowering agents at baseline, there 190 
was no significant association between HbA1c and the risk of retinal hemorrhage or diabetic 191 
retinal hemorrhage. There was no significant association between HbA1c and the risk of 192 
 non-diabetic retinal hemorrhage among subjects who were not taking medication for diabetes 193 
mellitus at baseline. 194 
Figure 1 shows the Kaplan–Meier plots for the five HbA1c categories and 195 
diabetic retinal hemorrhage among subjects not taking medication for diabetes mellitus at 196 
baseline. The proportion of subjects that were hemorrhage-free was 99.8% for those with 197 
HbA1c <5.7%, 96.3% for HbA1c ≥5.7 to <6.5%, 92.7% for HbA1c ≥6.5 to <7.3%, 45.9% for 198 
HbA1c ≥7.3 to <8.1%, and 38.1% for HbA1c ≥8.1% (P<0.001, log-rank test). 199 
Table 4 shows the multivariable-adjusted ORs and 95% CIs for cardiovascular 200 
risk factors for retinal hemorrhage and diabetic retinal hemorrhage among subjects not taking 201 
medication for diabetes mellitus at baseline. Age, BMI, and hypertension were positively 202 
associated with the risk of retinal hemorrhage (P<0.001, P=0.017, and P<0.001, respectively), 203 
while the initiation of cholesterol-lowering medication was inversely associated with the risk 204 
of hemorrhage (P=0.011). Smoking was positively associated with the risk of diabetic retinal 205 
hemorrhage (P=0.028).  206 
In addition, we examined the relationship between HbA1c and the risk of 207 
retinal hemorrhage in both eyes, and found similar results (Supplemental table 2). Compared 208 
with the referent group whose baseline HbA1c was < 5.7%, subjects with baseline HbA1c 209 
≥8.1% not taking medication for diabetes mellitus at baseline were had a 8.30-fold higher risk 210 
of retinal hemorrhage and a 240.22-fold higher risk of diabetic retinal hemorrhage (P<0.001 211 
and P<0.001, respectively). For subjects receiving glucose-lowering agents at baseline, there 212 
was no significant association between HbA1c and the risk of retinal hemorrhage or diabetic 213 
retinal hemorrhage. We also examined the relationship between HbA1c and the risk of retinal 214 
hemorrhage among workers. Compared with the referent group whose baseline HbA1c was < 215 
5.7%, subjects with baseline HbA1c ≥8.1% had a 3.10-fold higher risk of retinal hemorrhage 216 
 and a 248.12-fold higher risk of diabetic retinal hemorrhage (P<0.001 and P<0.001, 217 
respectively) (Supplemental Table 3).  218 
219 
 4. Discussion 220 
We found a significant positive relationship between HbA1c and the risk of subsequent 221 
retinal hemorrhage among subjects not taking medication for diabetes mellitus at baseline. 222 
This relationship was observed for both retinal hemorrhage and diabetic retinal hemorrhage. 223 
This is the first study that shows an association between HbA1c and the risk of retinal 224 
hemorrhage. The study also showed that aging, BMI, and hypertension were positively 225 
correlated with the risk of retinal hemorrhage, and initiation of treatment for 226 
hypercholesterolemia was inversely correlated with the risk of retinal hemorrhage. Smoking 227 
was positively correlated with the risk of diabetic retinal hemorrhage. These associations 228 
were observed among subjects not receiving medication for diabetes mellitus at baseline, but 229 
among not subjects on medication. 230 
Several previous studies have reported a positive relationship between HbA1c 231 
and the risk of diabetic retinopathy (3-5); however, the relationship between HbA1c(HbA1) 232 
and the risk of retinal hemorrhage was not reported. A Japanese study based on health 233 
check-ups used fundus photography to evaluate for diabetic retinopathy (5) based on Fukuda 234 
standard A2 or higher as the definition of diabetic retinopathy (9). In short, that study defined 235 
diabetic retinopathy as the presence of hard exudates, cotton wool spots, retinal hemorrhage, 236 
or more severe forms of retinopathy. Unfortunately, that study did not report the number of 237 
retinal hemorrhages or the association between HbA1c and the risk of retinal hemorrhage 238 
itself. Therefore, we could not compare our results with their results.  239 
In the present study, several cardiovascular risk factors were positively 240 
associated with the risk of retinal hemorrhage, such as hypertension, BMI, and smoking. For 241 
hypertension, initiation of anti-hypertensive medication was also inversely associated with 242 
the risk of retinal hemorrhage and diabetic retinal hemorrhage with borderline significance. 243 
Of course, the mechanism is unknown, but these findings imply that the prevention of retinal 244 
 hemorrhage is similar to the prevention of stroke, especially intraparenchymal hemorrhage, 245 
which is due to arterial necrosis and associated with susceptibility to arterial wall rupture 246 
(10). 247 
The methodology of the present study had certain strengths. It was a 248 
population-based prospective study, which is more representative of the general population 249 
than studies with hospital-based or volunteer samples. In addition, a prospective study has 250 
little recall bias, and the results of such studies support a potential causal relationship 251 
between risk factors and events.  252 
The present study also had limitations. First, the protocols of fundus 253 
photography varied among subjects, which may result in detection bias. The two lowest 254 
categories of HbA1c included subjects who took retinal photography biennially. Therefore, 255 
these categories may have not identified cases of retinal hemorrhage between surveys. 256 
However, we examined the association between HbA1c and the risk of retinal hemorrhage 257 
among workers because this group underwent fundus photography annually (Supplemental 258 
table 3). We confirmed the association between HbA1c and the risk of retinal hemorrhage did 259 
not change materially. Second, we used data from a single eye, usually the right eye. 260 
Therefore, we did not capture cases of retinal hemorrhage in the left eye. However, this 261 
detection bias shifts the results toward null and does not artificially create an apparent 262 
association between HbA1c and the risk of retinal hemorrhage. We performed some analyses 263 
with data from both eyes (Supplemental Table 2) and confirmed that the estimate of the 264 
association between HbA1c and the risk of retinal hemorrhage was not materially different. 265 
Third, we could not ascertain the precise incident time of retinal hemorrhage because our 266 
analysis was based on an annual cardiovascular disease risk survey. Therefore, we used 267 
logistic regression to calculate ORs. Fourth, we used two different outcomes, retinal 268 
hemorrhage and diabetic retinal hemorrhage, which constituted 18.9% of all retinal 269 
 hemorrhages. Although we defined diabetic retinal hemorrhage using the criteria stated in the 270 
Methods section, misclassification may have occurred. 271 
In conclusion, our prospective study of the Japanese general population 272 
demonstrated that HbA1c is positively associated with the risk of retinal hemorrhage among 273 
subjects not on glucose-lowering treatment at the time of the baseline survey. In addition, 274 
several cardiovascular risk factors such as hypertension are associated with the risk of retinal 275 
hemorrhage. 276 
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Table 1.　Number of retinal hemorrhages stratified by use of medication for diabetes mellitus at baseline
No medication for diabetes at baseline Medication for diabetes at baseline Total
  No. of subjects 11429 215 11644
  Person-years 53982 844 54826
  Retinal hemorrhage
     No. of events 451 58 509
  Diabetic retinal hemorrhage
     No. of events 41 55 96
  Non-diabetic retinal hemorrhage
     No. of events 410 3 413
Table 2.　Characteristics of subjects by HbA1c category at baseline
<5.7 ≥5.7 to <6.5 ≥6.5 to <7.3 ≥7.3 to <8.1 ≥8.1 <5.7 ≥5.7 to <6.5 ≥6.5 to <7.3 ≥7.3 to <8.1 ≥8.1
No. of subjects 10428 758 136 47 60 11 45 62 50 47
Age (years) 48.3 56.2** 55.6** 55.1** 54.1** 64.9 58.8 62.1 59.2 55.8**
Male (%) 60 60 65 77* 73* 73 67 81 74 70
Body mass index (kg/m2) 23.1 24.9** 25.6** 24.6** 25.1** 23.7 24.2 24.0 25.3 24.1
Current drinkers (%) 57 52** 50 57 58 58 55 54 60 59
Current smokers (%) 31 34 40* 37 53** 36 30 39 30 34
Systolic blood pressure (mmHg) 123 126** 129** 129** 128** 131 130 132 133 130
Diastolic blood pressure (mmHg) 77 79** 80** 79 78 78 76 78 79 77
Medication for hypertension at baseline (%) 11 14** 15 20* 5 40 40 35 34 28
Serum LDL cholesterol (mg/dL) 125 131** 134** 129 139** 99 121 128 127 128
Serum HDL cholesterol (mg/dL) 59 56** 54** 53** 53** 56 52 56 57 56
Medication for hypercholesterolemia at baseline (%) 4 9** 7 9 0 17 26 18 26 15
Initiation of glucose-lowering medication after baseline (%) 1 10** 41** 59** 58** - - - - -
Initiation of anti-hypertensive medication after baseline (%) 7 8 13** 13 8 8 10 4 12 7
Initiation of cholesterol-lowering medication after baseline (%) 5 7 11** 12 12* 10 9 10 4 14
Abbreviations: HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; HDL, high-density lipoprotein. 
Difference from the lowest category *P <0.05 **P <0.01
Except for age and male sex, values shown were adjusted for age and sex.
No medication for diabetes mellitus at baseline Medication for diabetes mellitus at baseline
HbA1c (%) HbA1c (%)
Table 3. Associations between HbA1c and risk of retinal hemorrhage in one eye
<5.7
No. of subjects 10428
No. of events 375
Incidence (/1000 person-years) 7.5
Multivariable-adjusted OR and 95%CIa 1.00 0.90 （ 0.64 - 1.28 ） 1.17 （ 0.58 - 2.37 ） 4.66 （ 2.14 - 10.16 ） 5.41 （ 2.71 - 10.81 ）
No. of events 7
Incidence (/1000 person years) 0.1
Multivariable-adjusted OR and 95%CIa 1.00 11.26 （ 3.74 - 33.89 ） 44.51 （ 12.77 - 155.11 ） 233.08 （ 67.68 - 802.65 ） 238.87 （ 74.36 - 767.38 ）
No. of subjects 11
No. of events 2
Incidence (/1000 person-years) 30.5
Multivariable-adjusted OR and 95%CIa 1.00 1.00 （ 0.17 - 5.70 ） 1.43 （ 0.27 - 7.72 ） 1.87 （ 0.34 - 10.33 ） 2.20 （ 0.40 - 12.23 ）
No. of events 2
Incidence (/1000 person-years) 30.5
Multivariable-adjusted OR and 95%CIa 1.00 0.99 （ 0.17 - 5.65 ） 1.25 （ 0.23 - 6.77 ） 1.83 （ 0.33 - 10.15 ） 1.80 （ 0.32 - 10.05 ）
Abbreviations: CI, confidence interval; OR, odds ratio; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; HDL, high-density lipoprotein..
HbA1c (%)
≥5.7 to <6.5 ≥6.5 to <7.3 ≥7.3 to <8.1 ≥8.1
No medication for diabetes at baseline
758 136 47 60
  Retinal hemorrhage
40 10 11 15
13.3 16.7 45.8 68.4
  Diabetic retinal hemorrhage
7 6 9 12
2.3 10.0 37.5 54.7
Medication for diabetes at baseline
45 62 50 47
  Retinal hemorrhage
9 15 15 17
43.8 61.9 86.8 108.0
aAdjusted for age, sex, body mass index, current drinker, current smoker, hypertension, serum LDL cholesterol (10 mg/dL), serum HDL cholesterol (10 mg/dL), initiation of glucose-
lowering medication, initiation of antihypertensive medication, and initiation of cholesterol-lowering medication.
  Diabetic retinal hemorrhage
9 14 15 15
43.8 57.8 86.8 95.3
Table 4. Multivariable-adjusted odds ratios for cardiovascular risk factors for retinal hemorrhage in a single eye among subjects not taking medication for diabetes mellitus at baseline
P P
No. of subjects
No. of events
Age (years)a 1.04 ( 1.03 - 1.05 ) <0.001 1.02 ( 0.99 - 1.06 ) 0.250
Sex (female)a 1.14 ( 0.89 - 1.47 ) 0.306 0.76 ( 0.30 - 1.96 ) 0.572
BMI (kg/m2)a 1.03 ( 1.00 - 1.06 ) 0.017 0.97 ( 0.88 - 1.07 ) 0.559
Current smokera 1.24 ( 0.98 - 1.56 ) 0.077 2.44 ( 1.10 - 5.41 ) 0.028
Current drinkera 0.82 ( 0.65 - 1.04 ) 0.099 0.56 ( 0.24 - 1.30 ) 0.176
Hypertensiona 2.19 ( 1.76 - 2.73 ) <0.001 1.72 ( 0.83 - 3.57 ) 0.147
Serum LDL cholesterol (10 mg/dL)a 1.01 ( 0.97 - 1.04 ) 0.759 0.95 ( 0.86 - 1.05 ) 0.311
Serum HDL cholesterol (10 mg/dL)a 0.98 ( 0.91 - 1.05 ) 0.537 1.16 ( 0.90 - 1.50 ) 0.258
Initiation of glucose-lowering medication after baseline examinationa 1.44 ( 0.85 - 2.44 ) 0.174 2.11 ( 0.90 - 4.93 ) 0.087
Initiation of anti-hypertensive medication after baseline examinationa 0.74 ( 0.52 - 1.06 ) 0.096 0.22 ( 0.05 - 1.03 ) 0.054
Initiation of cholesterol-lowering medication after baseline examinationa 0.56 ( 0.35 - 0.87 ) 0.011 1.31 ( 0.43 - 4.01 ) 0.633
Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; HDL, high-density lipoprotein..
aAdjusted for HbA1c categories and the other variables.
Retinal hemorrhage  Diabetic retinal hemorrhage
11429 11429
451 41
Supplementary Table 1.　Characteristics of subjects stratified by background at baseline
Residents Workers
No. of subjects 4834 6810
Age (years) 56.3 44.0**
Male (%) 38 76**
Body mass index (kg/m2) 23.5 23.1**
Current drinkers (%) 51 61**
Current smokers (%) 32 31
Systolic blood pressure (mmHg) 125 122**
Diastolic blood pressure (mmHg) 79 76**
Medication for hypertension at baseline (%) 12 11
Serum LDL cholesterol (mg/dL) 125 126*
Serum HDL cholesterol (mg/dL) 60 58**
Medication for hypercholesterolemia at baseline (%) 4 5**
Initiation of glucose-lowering medication after baseline (%) 2 2
Initiation of anti-hypertensive medication after baseline (%) 9 6**
Initiation of cholesterol-lowering medication after baseline (%) 7 5**
HbA1c (%) 5.2 5.2
Medication for diabetes mellitus at baseline (%) 2 2
Difference between affiliations *P <0.05 **P <0.01
Except for age and male sex, values shown were adjusted for age and sex.
Supplementary Table 2. Associations between HbA1c and risk of retinal hemorrhage in both eyes
<5.7
No medication for diabetes at baseline
No. of subjects 10414
No. of events 400
Incidence (/1000 person-years) 8.0
Multivariable-adjusted OR and 95%CIa 1.00 1.11 （ 0.81 - 1.52 ） 2.04 （ 1.15 - 3.62 ） 5.16 （ 2.46 - 10.85 ） 8.30 （ 4.41 - 15.62 ）
No. of events 11
Incidence (/1000 person years) 0.2
Multivariable-adjusted OR and 95%CIa 1.00 11.99 （ 5.14 - 27.98 ） 35.93 （ 12.70 - 101.68 ） 121.10 （ 40.29 - 363.95 ） 240.22 （ 91.46 - 630.89 ）
No. of subjects 11
No. of events 2
Incidence of events (/1000 person years) 30.5
Multivariable-adjusted OR and 95%CIa 1.00 1.18 （ 0.21 - 6.65 ） 2.15 （ 0.40 - 11.57 ） 2.31 （ 0.42 - 12.72 ） 2.83 （ 0.51 - 15.69 ）
No. of events 2
Incidence (/1000 person-years) 30.5
Multivariable-adjusted OR and 95%CIa 1.00 1.05 （ 0.19 - 5.96 ） 1.55 （ 0.29 - 8.37 ） 2.07 （ 0.38 - 11.35 ） 2.33 （ 0.42 - 12.85 ）
Abbreviations: CI, confidence interval; OR, odds ratio; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; HDL, high-density lipoprotein..
HbA1c (%)
≥5.7 to <6.5 ≥6.5 to <7.3 ≥7.3 to <8.1 ≥8.1
757 136 47 60
  Retinal hemorrhage
52 17 12 20
17.4 28.9 52.0 95.5
  Diabetic retinal hemorrhage
13 8 8 17
4.4 13.6 34.7 81.2
Medication for diabetes at baseline
45 62 50 47
  Retinal hemorrhage
11 19 18 20
55.4 87.4 112.7 145.7
aAdjusted for age, sex, body mass index (kg/m2), current drinker, current smoker, hypertension, serum LDL cholesterol levels (10 mg/dL), serum HDL cholesterol levels (10 mg/dL), start
of glucose-lowering medication use, start of antihypertensive medication use and start of cholesterol-lowering medication use.
  Diabetic retinal hemorrhage
10 16 17 18
50.4 73.6 106.4 131.1
Supplementary Table 3. Associations between HbA1c level and risk of retinal hemorrhage in single eyes among workers
<5.7
No. of subjects 6264
No. of events 177
Incidence (/1000 person-years) 6.5
Multivariable-adjusted OR and 95%CIa 1.00 0.43 （ 0.20 - 0.94 ） 0.73 （ 0.21 - 2.62 ） 8.36 （ 2.98 - 23.47 ） 3.10 （ 1.01 - 9.54 ）
No. of events 3
Incidence (/1000 person-years) 0.1
Multivariable-adjusted OR and 95%CIa 1.00 11.04 （ 1.57 - 77.88 ） 22.87 （ 1.57 - 332.62 ） 845.33 （ 134.97 - >999.99） 248.12 （ 39.03 - >999.99）
No. of subjects 0
No. of events 0
Incidence (/1000 person-years) -
Multivariable-adjusted OR and 95%CIa -
No. of events 0
Incidence (/1000 person-years) -
Multivariable-adjusted OR and 95%CIa -
Abbreviations: CI, confidence interval; OR, odds ratio; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; HDL, high-density lipoprotein..
HbA1c (%)
≥5.7 to <6.5 ≥6.5 to <7.3 ≥7.3 to <8.1 ≥8.1
No medication for diabetes at baseline
329 64 24 32
  Retinal hemorrhage
7 3 7 5
6.8 10.5 53.5 44.3
  Diabetic retinal hemorrhage
2 1 7 5
2.0 3.5 53.5 44.3
Medication for diabetes at baseline
20 27 27 23
  Retinal hemorrhage
3 1 12 7
35.8 11.7 162.3 128.7
- - - -
  Diabetic retinal hemorrhage
3 0 12 6
aAdjusted for age, sex, body mass index (kg/m2), current drinker, current smoker, hypertension, serum LDL cholesterol (10 mg/dL), serum HDL cholesterol (10 mg/dL), initiation of glucose-
lowering medication, initiation of antihypertensive medication, and initiation of cholesterol-lowering medication.
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Figure 1  Kaplan–Meier plot for five HbA1c categories associated with diabetic 
retinal hemorrhage among subjects not receiving medication for diabetes mellitus at 
baseline
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